(≥10µm) #/Container by microscopic method

5°C, Months	PEG 3350 Conc. (w/v)			Poloxamer 188 Conc. (w/v)		
	0.02%	0.04%	0.1%	0.02%	0.04%	0.1%
6	15	38	99	36	34	84
12	23	61	36	42	25	34
18	25	42	38	86	40	114
24	61	103	57	91	105	143
36	25	17	38	32	19	67

(≥25µm) #/Container by microscopic method

5°C, Months	PEG 3350 Conc. (w/v)			Poloxamer 188 Conc. (w/v)		
	0.02%	0.04%	0.1%	0.02%	0.04%	0.1%
6	0	11	42	17	2	19
12	6	19	11	17	8	4
18	8	6	11	21	4	30
24	8	13	11	11	15	15
36	15	0	6	2	4	17

FIG. 1



Stability of 150 mg/mL IL-4R Antibody Against Agitation
30 min
60 min
120 min
% HMW
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0.000
0.010
0.020
0.030
0.040
0.050
PEG3350 Concentration (% w/v)

FIG. 2A



Stability of 150 mg/mL IL-4R Antibody
Against Agitation
30 min
60 min
120 min
MWH %
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0.00
0.01
0.02
0.03
0.04
0.05
Poloxamer 188 Concentration (% w/v)

FIG. 2B



Thermal Stability of 150 mg/mL IL-4R Antibody - Cosolvent Screening
No Cosolvent
0.2% PS-20
0.2% PS-20
0.1% PS-20
0.05% PS-20
0.1% PS-80
0.05% PS-80
0.025% PS-80
0.02% PEG3350
0.01% PEG3350
0.02% Poloxamer
0.01% Poloxamer
% HMW (SE-UPLC)
14
12
10
8
6
4
2
0
10
20
30
40
50
60
Incubation Time at 45°C (days)

FIG. 3